Continuous subcutaneous insulin infusion therapy: long-term impact upon plasma lipids, lipoproteins and HbA1c

Webb, R.J. and Davies, I.G. and Purewal, T.S. and Weston, P.J. and Morrison, G. and Abayomi, J.C. (2014) Continuous subcutaneous insulin infusion therapy: long-term impact upon plasma lipids, lipoproteins and HbA1c. Diabetic Medicine, 31 (S1). ISSN 0742-3071

Full text not available from this repository.


Aims: Patients with Type 1 diabetes and poor glycaemic control frequently display unfavourable lipid profiles, increasing the risk of premature atherosclerosis development. Conversely, patients possessing optimal glycaemic control display lipid profiles comparable to those without diabetes1. Continuous subcutaneous insulin infusion (CSII) has been shown to significantly improve glycaemic control, however there have been few studies investigating the impact this therapy may have upon long-term plasma lipid profiles2.
Method: Medical records containing routine plasma lipid, lipoprotein and HbA1c measurements from patients undergoing CSII therapy at the Royal Liverpool and Broadgreen University Hospital were utilised. Data contained in these records spanning a 4 year period were analysed within SPSS software using descriptive, one-way ANOVA and bivariate correlation tests.
Results: The study population consisted of 268 patients (35.1% male, 64.9% female); mean age (45±9 years). One-way ANOVA results showed significant mean reductions in HbA1c from 8.46±1.26 to 7.99±1.29% (p<0.000). Mean total cholesterol significantly decreased from 4.32±1.14 to 4.18±0.94mmol/l (p<0.004). Non-significant reductions from 1.13±0.61 to 0.97±0.48mmol/l (p<0.843) were also shown in plasma triglycerides. There were no significant changes in mean HDL (p<0.44) and LDL, although significance was seen between LDL time points (p<0.005). Bivariate correlation analysis demonstrated a small, significant relationship with triglycerides and HbA1c (r = 0.121) (p<0.001).
Conclusions: These findings are in agreement with existing literature which suggests CSII often improves glycaemic control. The results also indicate CSII therapy may be associated with favourable improvements in lipid profile, which may in turn lead to a reduction in cardiovascular disease risk.

Item Type: Article
Faculty / Department: Faculty of Science > School of Health Sciences
Depositing User: Richard Webb
Date Deposited: 18 Dec 2018 11:54
Last Modified: 18 Dec 2018 11:54

Actions (login required)

View Item View Item